

CO-ORGANIZED BY



FONDAZIONE  
MENARINI



Endorsed by  
**ESTRO**



FONDAZIONE RADIOTERAPIA ONCOLOGICA

**50**  
YEARS OF  
FONDAZIONE  
MENARINI

# 2<sup>ND</sup> INTERNATIONAL MULTIDISCIPLINARY CONSENSUS ON THE INTEGRATION OF RADIATION THERAPY WITH NEW SYSTEMIC TREATMENTS

European Society for Radiation Therapy and Oncology (ESTRO) - Endorsed Recommendations



[WWW.FONDAZIONE-MENARINI.COM](http://WWW.FONDAZIONE-MENARINI.COM)

**8<sup>th</sup> – 10<sup>th</sup> October 2026 - Florence (Italy)**

*Venue: FH55 Grand Hotel Mediterraneo - Lungarno del Tempio, 44, 50121 Firenze (FI)*

## INTRODUCTION

This consensus project, scheduled for Friday-Saturday 9-10 October 2026, is conceived as a high-level scientific educational event dedicated to multidisciplinary updates on the most recent innovations in the treatment of major high-incidence solid tumours: head and neck, prostate, kidney and breast cancer.

The evolution of modern oncology is characterised by an increasing integration between innovative systemic therapies (immunotherapy, targeted therapies, antibody-drug conjugates, PARP inhibitors) and precision radiation therapy, with a significant impact on clinical outcomes, patients' quality of life, and the sustainability of care pathways. In this context, it is essential for healthcare professionals to acquire up-to-date knowledge not only on individual therapeutic strategies, but above all on their rational and sequential integration.

The scientific programme is structured around keynote lectures delivered by internationally recognised experts, addressing:

- the role of the tumour micro-environment and the biological mechanisms underlying response and resistance to therapies;
- the transformative impact of immunotherapy in head and neck tumours and breast cancer;
- the evolution of systemic strategies in genitourinary tumours, with particular attention to metastatic disease;
- technological and clinical advances in radiation therapy, and how to translate technical innovation into tangible clinical benefit;
- new perspectives in clinical trial design and therapeutic sequencing, particularly in advanced breast cancer;
- the growing role of patient engagement and advocacy in oncological care pathways.

The event addresses concrete and current educational needs of healthcare professionals, promoting:

- evidence-based updates on emerging therapeutic options;
- multidisciplinary discussion among medical oncologists, radiation oncologists, surgeons and other specialists;
- enhanced decision-making skills in daily clinical practice, aligned with the most recent scientific evidence and international guidelines.

In light of the increasing complexity of oncological treatments and the **rapid evolution of knowledge, the congress represents an essential educational opportunity to ensure clinical appropriateness, treatment safety and continuous improvement in the quality of care.**

### CO-PRESIDENTS

Lorenzo Livi

Icro Meattini

Pierluigi Bonomo

Giulio Francolini

## UNDER THE AUSPICES OF



Endorsed by<sup>1</sup>  
**ESTRO**



## CO-PRESIDENTS OF THE MEETING

**Lorenzo Livi**  
**Icro Meattini**  
**Pierluigi Bonomo**  
**Giulio Francolini**

## CO-ORGANIZED BY



FONDAZIONE  
MENARINI

**Fondazione Menarini**  
Centro Direzionale Milanofiori  
I-20089 Rozzano (Milan, Italy)  
Strada 8 – Edificio N  
Phone +39 02 55308110 - Fax +39 02 55305739  
milan@fondazione-menarini.it  
www.fondazione-menarini.com

## SCIENTIFIC AND ORGANIZING SECRETARIAT

**Hinovia Events srl**  
Via Guelfa, 114  
50129 Florence (Italy)

**PROGRAMME**

**THURSDAY, 8<sup>TH</sup> OCTOBER 2026 - AFTERNOON**

05.00 p.m. - 07.00 p.m. Pre-meeting alignment  
All Faculty

**FRIDAY, 9<sup>TH</sup> OCTOBER 2026 - MORNING**

07.00 a.m. - 08.00 a.m. Registration

08.00 a.m. - 08.30 a.m. Welcome and Introduction  
**L. Livi, I. Meattini, P. Bonomo, G. Francolini**  
**Fondazione Menarini**

08.30 a.m. - 09.00 a.m. From Diagnosis to Treatment: The Promise and  
Responsibility of Theranostics  
**G. Curigliano, B. Jereczek**

**HEAD NECK**

**SESSION I - PROGNOSTIC AND PREDICTIVE FACTORS  
FOR PERSONALIZED TREATMENT IN LOCALLY  
ADVANCED HEAD AND NECK SQUAMOUS  
CELL CARCINOMA (HNSCC)**

Chairpersons: **H. Langendijk, W. N. William, J. Cacicedo**

09.00 a.m. - 09.20 a.m. Dissecting the molecular landscape of HNSCC: a vision  
for the future  
**I. Tinhofer**

09.20 a.m. - 09.40 a.m. From bench to bedside: challenges and opportunities  
for personalised treatment in HNSCC  
**K. Harrington**

09.40 a.m. - 10.00 a.m. Panel discussion / Q&A  
**P. Balermpas, I. Brana, P. Szturz**

**SESSION II - INTEGRATING RADIATION THERAPY WITH SYSTEMIC TREATMENTS FOR RECURRENT/ METASTATIC HNSCC**

Chairpersons: **J. Eriksen, M. G. Ghi, G. Castro Jr**

10.00 a.m. - 10.20 a.m.

Optimizing loco-regional control in de-novo metastatic HNSCC: is the gain worth the effort?  
**M. Evans**

10.20 a.m. - 10.40 a.m.

Navigating treatment options in (oligo)metastatic CPS positive patients: is “cure” a reasonable goal?  
**P. Bossi**

10.40 a.m. - 11.00 a.m.

Panel discussion / Q&A  
**T. Fuereder, F. De Felice, K. Prabash**

**KEYNOTE LECTURE**

**RAISING THE BAR OF CURE FOR LOCALLY ADVANCED HNSCC: IMMUNOTHERAPY AND BEYOND**

Chairpersons: **R. Mesia, S. Tribius**

11.00 a.m. - 11.30 a.m.

A personal journey in the treatment of head and neck squamous cell carcinoma  
**L. Licitra**

**SESSION III - PERSONALIZING TREATMENT OF LOCALLY ADVANCED NASOPHARYNGEAL CANCER**

Chairpersons: **E. Orlandi, N. Lee, A. Spreafico**

11.30 a.m. - 11.50 a.m.

How and to whom intensify induction chemo-immunotherapy?  
**B. Ma**

11.50 a.m. - 12.10 p.m.

How and to whom de-escalate chemo-radiation after induction chemo-immunotherapy?  
**J. Ma**

12.10 p.m. - 12.30 p.m.

Panel discussion / Q&A  
**M. Mejia, B. Keam, S. Alfieri**

**SESSION IV - INTEGRATING RADIATION THERAPY WITH SYSTEMIC TREATMENT FOR RECURRENT/METASTATIC NASOPHARYNGEAL CANCER**

Chairpersons: **A. W.M. Lee, D. Wan Teck Lim, L. Locati**

- 12.30 p.m. - 12.50 p.m. Integrating molecular and imaging biomarkers in the decision-making: how to select the best sequence of treatment?  
**M. Chua**
- 12.50 p.m. - 01.10 p.m. Optimizing loco-regional control in de-novo metastatic NPC: is the gain worth the effort?  
**S. Huang**
- 01.10 p.m. - 01.30 p.m. Panel discussion / Q&A  
**Q.T. Le, W. Zamaniah, S. Yom**
- 01.30 p.m. - 02.30 p.m. *Lunch*

**FRIDAY, 9<sup>TH</sup> OCTOBER 2026 - AFTERNOON**

**BREAST**

**SESSION I - CDK4/6 INHIBITORS & ENDOCRINE THERAPY**

Chairpersons: **B. V. Offersen, S. Paluch Simon**

- 02.30 p.m. - 02.50 p.m. CDK4/6 Inhibitors in HR+/HER2- Early Breast Cancer: Current Evidence, Indications and Evolving Clinical Use  
**M. Lambertini**
- 02.50 p.m. - 03.10 p.m. Integrating CDK4/6 Inhibitors with Radiation therapy: Timing, Toxicity Signals and Practical Clinical Recommendations  
**G. N. Marta**
- 03.10 p.m. - 03.30 p.m. Panel discussion / Q&A

**SESSION II - PARP INHIBITORS & IMMUNOTHERAPY**

Chairpersons: **A. Gennari, A. L. Montero**

03.30 p.m. - 03.50 p.m. PARP Inhibitors and Immunotherapy: Radiobiological Rationale and Emerging Evidence for Combination with Radiation therapy

**O. Kaidar-Person**

03.50 p.m. - 04.10 p.m. PARPi and Immunotherapy in Breast Cancer: Clinical Evidence, Patient Selection and Therapeutic Indications

**Sanchez-Bayona R**

04.10 p.m. - 04.30 p.m. Panel discussion / Q&A

**KEYNOTE LECTURE  
TARGETED RADIONUCLIDE THERAPY**

Chairpersons: **C. E. Coles, C. Isacke**

04.30 p.m. - 04.45 p.m. Targeted Radionuclide Therapy in Breast Cancer: Biological Foundations and the Path Toward Clinical Translation

**C. Jones**

**KEYNOTE LECTURE  
PRECLINICAL INSIGHTS**

Chairpersons: **R. Clarke, A. Morandi**

04.45 p.m. - 05.00 p.m. Preclinical Insights into Radiation Therapy Resistance: Biological Drivers and Research Priorities

**S. Rottenberg**

**SESSION III - ANTI-HER AGENTS & ADCS**

Chairpersons: **L. J. Boersma, N. Harbeck**

- 05.00 p.m. - 05.20 p.m. Anti-HER2 Therapies and ADCs: Clinical Indications, Efficacy and Evolving Treatment Landscape  
**C. Saura**
- 05.20 p.m. - 05.40 p.m. Anti-HER2 Agents and ADCs with Radiation therapy: Safety, Timing and Current Integration Evidence  
**S. Alkner**
- 05.40 p.m. - 06.00 p.m. Panel discussion / Q&A

**SESSION IV - CLASSICAL CHEMOTHERAPY**

Chairpersons: **M. Maraldo, D. Krug**

- 06.00 p.m. - 06.20 p.m. Radiation therapy After Anthracyclines and Taxanes: Timing, Acute and Late Toxicity, and Evidence-Based Integration  
**I. Ratos**
- 06.20 p.m. - 06.40 p.m. Classical Chemotherapy in Early and Locally Advanced Breast Cancer: Current Standards and Treatment Indications  
**M. Ekholm**
- 06.40 p.m. - 07.00 p.m. Panel discussion / Q&A
- 07.00 p.m. - 07.15 p.m. Survey Event: Satisfaction survey with certificate

**SATURDAY, 10<sup>TH</sup> OCTOBER 2026 - MORNING**

08.30 a.m. - 09.00 a.m. Opening Day 2

**PROSTATE / KIDNEY**

**OLIGOMETASTATIC PROSTATE CANCER, HORMONE SENSITIVE SCENARIO**

Chairpersons: **S. Gillessen, M. Roach**

09.00 a.m. - 09.20 a.m. SBRT alone as a tool to delay systemic treatment start  
**M. Miszczyk**

09.20 a.m. - 09.40 a.m. Concurrent administration of SBRT and ADT+/-ARPIs  
**C. Zamboglou**

09.40 a.m. - 10.00 a.m. Panel discussion / Q&A

**OLIGOMETASTATIC PROSTATE CANCER, CASTRATION RESISTANT SCENARIO**

Chairpersons: **G. Francolini, Y. Urun**

10.00 a.m. - 10.20 a.m. Use of SBRT in oligometastatic castrate resistant prostate cancer  
**A. Pathmanathan**

10.20 a.m. - 10.40 a.m. Special situations, concurrent SBRT with PARPIs and radioligand therapies  
**T. Phuoc**

10.40 a.m. - 11.00 a.m. Panel discussion / Q&A

**KEYNOTE LECTURE**

Chairpersons: **M. Di Maio, M. Roach**

11.00 a.m. - 11.30 a.m. A glance to the future: upcoming systemic treatment intensification strategies in metastatic hormone-sensitive prostate cancer  
**S. Gillessen**

**OLIGOMETASTATIC KIDNEY CANCER, SBRT USED OUTSIDE IO COMBINATIONS**

Chairpersons: **Y. Urun, C. Tang**

11.30 a.m. - 11.50 a.m. SBRT alone as a tool to delay systemic treatment start  
**A. Bruynzeel**

11.50 a.m. - 12.10 p.m. Use of concomitant SBRT and TKI treatment in the oligometastatic/oligoprogressive scenario  
**R. Hannan**

12.10 p.m. - 12.30 p.m. Panel discussion / Q&A

**OLIGOMETASTATIC KIDNEY CANCER, RT WITH SYSTEMIC THERAPY IN CONTEMPORARY PRACTICE: WHEN IO COMBINATIONS ARE USED**

Chairpersons: **C. Tang, B. Rini**

12.30 a.m. - 12.50 p.m. SBRT added to current IO treatment options, evidence and future perspectives  
**A. Swaminath**

12.50 p.m. - 01.10 p.m. Local treatment for primary tumor in metastatic RCC, actual evidence and ongoing trials  
**R. Iacovelli**

01.10 p.m. - 01.30 p.m. Panel discussion / Q&A

01.30 p.m. - 02.30 p.m. *Lunch*

**KEYNOTE LECTURE (ALL FACULTY)**

Chairpersons: **A. M. Kirby, T. Spanic**

02.30 p.m. - 03.00 p.m. Equity, culture, leadership, and patient-centred care  
**R. Jagsi**

**FINAL CONSENSUS PRESENTATION**

Chairpersons: **P. Bossi, K. Harrington, I. Meattini, H. Rugo, H. Stobart, A. Tree, S. Gillissen**

03.00 p.m. - 03.30 p.m. Head & Neck  
**P. Bonomo**

03.30 p.m. - 04.00 p.m. Breast Cancer  
**C. Becherini**

04.00 p.m. - 04.30 p.m. Prostate/Kidney  
**G. Francolini**

04.30 p.m. - 05.00 p.m. Closing Remarks  
**L. Livi, I. Meattini, P. Bonomo, G. Francolini**

05.00 p.m. - 05.15 p.m. Survey Event: Satisfaction survey with certificate

**FACULTY**

---

**S. Alfieri**

---

**S. Alkner**

---

**C. Becherini**

---

**L. J. Boersma**

---

**P. Bossi**

---

**A. Bruynzeel**

---

**G. Castro Jr**

---

**M. Chua**

---

**R. Clarke**

---

**C. E. Coles**

---

**F. De Felice**

---

**M. Di Maio**

---

**M. Ekholm**

---

**M. Evans**

---

**G. Francolini**

---

**T. Fuereder**

---

**A. Gennari**

---

**M. G. Ghi**

---

**FACULTY**

---

**S. Gillessen**

---

**N. Harbeck**

---

**R. Hannan**

---

**K. Harrington**

---

**S. Huang**

---

**C. Isacke**

---

**R. Iacovelli**

---

**R. Jagsi**

---

**O. Kaidar-Person**

---

**B. Keam**

---

**A. M. Kirby**

---

**D. Krug**

---

**M. Lambertini**

---

**Q.T. Le**

---

**N. Lee**

---

**W.M. Lee**

---

**L. Licitra**

---

**L. Locati**

---

**FACULTY**

---

**J. Ma**

---

**B. Ma**

---

**M. Maraldo**

---

**G. N. Marta**

---

**I. Meattini**

---

**M. Mejia**

---

**R. Mesia**

---

**M. Miszczyk**

---

**A. L. Montero**

---

**A. Morandi**

---

**B. V. Offersen**

---

**E. Orlandi**

---

**S. Paluch Simon**

---

**K. Prabash**

---

**I. Ratosá**

---

**B. Rini**

---

**M. Roach**

---

**FACULTY**

---

**S. Rottenberg**

---

**H. Rugo**

---

**C. Saura**

---

**R. Sanchez-Bayona**

---

**A. Spreafico**

---

**T. Spanic**

---

**H. Stobart**

---

**A. Swaminath**

---

**C. Tang**

---

**A. Tree**

---

**S. Tribius**

---

**D. Wan Teck Lim**

---

**S. Yom**

---

**W. Zamaniah**

---

**C. Zamboglou**

---

# 2<sup>ND</sup> INTERNATIONAL MULTIDISCIPLINARY CONSENSUS ON THE INTEGRATION OF RADIATION THERAPY WITH NEW SYSTEMIC TREATMENTS

European Society for Radiation Therapy and Oncology (ESTRO)

## GENERAL INFORMATION

### VENUE

FH55 Grand Hotel Mediterraneo  
Lungarno del Tempio, 44, 50121 Firenze FI

### SECRETARIAT DURING THE MEETING

The Secretariat will be open at the following times:  
Friday, 9<sup>th</sup> October from 09:00 am to 05:30 pm  
Saturday, 10<sup>th</sup> October from 09:00 am to 06:00 pm

### OFFICIAL LANGUAGE

The official language of the Meeting will be English

### REGISTRATION

The meeting is free to attend.  
For more information and to register please visit the following website:  
[www.fondazione-menarini.com](http://www.fondazione-menarini.com)

### TECHNICAL FACILITIES

Facilities will be available for computer presentations and overhead projections.  
A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the business center at least one hour before the session starts.

The center will be open at the following times:  
Friday, 9<sup>th</sup> October from 09:00 am to 05:30 pm  
Saturday, 10<sup>th</sup> October from 09:00 am to 06:00 pm

### LUNCHESS AND COFFEE BREAKS


Lunches and coffee breaks will be served in the Meeting area.

### ATTENDANCE CERTIFICATE AND SURVEY

At the end of each day, faculty members and participants will have the possibility to answer a short appreciation questionnaire accessible using the QR code projected on the screen. After completing the survey it will immediately be possible to download the Attendance Certificate which can be kept, printed and shared.



FONDAZIONE  
MENARINI



[www.fondazione-menarini.com](http://www.fondazione-menarini.com)

All slides and presentations are available on our website 15 days after the event.

CO-ORGANIZED BY



FONDAZIONE  
MENARINI



Follow us on: [WWW.FONDAZIONE-MENARINI.COM](http://WWW.FONDAZIONE-MENARINI.COM)

Scan the QR code and  
immediately download  
the new APP.



Fondazione  
Menarini  
is also on [LinkedIn](#)